Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

B cells and multiple sclerosis.
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.
The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.
Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS.
[The membrane stabilizing effect of glatiramer acetate in multiple sclerosis].
New York Academy of Sciences: T Cells at the Interface of Immune-CNS Cross-Talk
Drug Safety Labeling Changes
Individual axons regulate the myelinating potential of single oligodendrocytes in vivo.
Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis.
Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review.
Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects.
Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
Natalizumab Use During the Third Trimester of Pregnancy.
LKB1-regulated adaptive mechanisms are essential for neuronal survival following mitochondrial dysfunction.
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
Genzyme receives positive CHMP opinion in the European Union for once-daily, oral AUBAGIO® to treat relapsing-remitting multiple sclerosis
Gordon Research Conference on Immunochemistry & Immunobiology
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Patient reported outcome measures in neurogenic bladder.
Selective inhibition of the mitochondrial permeability transition pore protects against neuro-degeneration in experimental multiple sclerosis.
Biogen Idec receives negative opinion from the CHMP on Fampyra
Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
Acorda Therapeutics announces initiation of AMPYRA® proof-of-concept study in patients with post-stroke deficits

Pages